Alvesco is owned by Covis.
Alvesco contains Ciclesonide.
Alvesco has a total of 1 drug patent out of which 0 drug patents have expired.
Alvesco was authorised for market use on 10 January, 2008.
Alvesco is available in aerosol, metered;inhalation dosage forms.
Alvesco can be used as maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child.
The generics of Alvesco are possible to be released after 01 February, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8371292||COVIS||Use of ciclesonide for the treatment of respiratory diseases|| |
(5 years from now)
Market Authorisation Date: 10 January, 2008
Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child
Dosage: AEROSOL, METERED;INHALATION
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic